Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment
option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge. It
is believed that decreased tumor burden before HSCT is a favourable factor contributing to
the long-term survival of R/R patients and many kinds of bridging chemotherapy regimens were
devised to kill leukemic cells before HSCT, there is still no consensus that which regimen is
optimal. This study is to investigate the curative efficacy and safty of bridging CAV
(cladribine combined with venetoclax and low dose Ara-C ) regimens followed by HSCT treatment
proctocal for R/R AML.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University